Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01408381
Other study ID # CMMo/ICC/2009
Secondary ID 2009-013636-20
Status Completed
Phase Phase 2
First received August 1, 2011
Last updated March 15, 2016
Start date January 2011
Est. completion date June 2015

Study information

Verified date March 2016
Source Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud
Contact n/a
Is FDA regulated No
Health authority Spain: Spanish Agency of Medicines
Study type Interventional

Clinical Trial Summary

Phase II Clinical Trial, a prospective, multicenter, open, randomized, parallel-group controlled with three levels of dose.

The hypothesis of the test we propose is that the mononuclear cells of bone marrow provide progenitor cells with regenerative capacity and besides secrete several angiogenic factors, and their implantation into ischemic tissues with both elements should contribute to angiogenesis and tissue regeneration with recovery of the circulation in the affected limb.


Description:

The study population will consist of a total of 44 non-diabetic patients with chronic critical ischemia in at least one of their lower limbs (CLI) and without possibility of revascularization. In the experimental group will be included a total of 33 patients divided into three levels of dose, 11 patients in each level (increasing dose of mononuclear cells from autologous bone marrow) and other 11 patients in control group.

- 11 patients in group 1 will not receive cell therapy, and they will only receive conventional treatment, acting as a control group.

- 11 patients in group 2 will receive 1x108 autologous bone marrow mononuclear cells.

- 11 patients in group 3 will receive 5x108 autologous bone marrow mononuclear cells.

- 11 patients in group 4 will receive 1x109 autologous bone marrow mononuclear cells.

The cell therapy drug will be administered intra-arterially in all cases. Patients will be evaluated by clinical, radiological and angiological methods (ankle / brachial pressure index, transcutaneous oxygen pressure, perimeter calf muscle, presence of ulcers, oximetry and digital arteriography).

Patients will receive concomitant drug treatment established by the good clinical practice, so undoubtedly it could be possible that some improvement occurs due to drug treatment.

It is estimated that the inclusion period is approximately 42 months, and the follow-up of each patient of six months. Therefore the total duration of the study will be about forty eight months from the entry of the first patient to the end of the follow-up period of the last patient included.

The primary variable is the improvement in the vascularisation of the treated limb determined by clinical, angiographic and angiologist parameters.

Study objectives :

• Main objective: To evaluate the safety and feasibility of the autotransplantation of autologous bone marrow mononuclear cells administered intra-arterially in non-diabetic patients with critical chronic ischemia of the lower limbs without possibility of either revascularization or other therapeutic alternatives.

Secondary objectives:

1. To compare the effect of three increasing dose of mononuclear cells from autologous bone marrow in the recovery of clinical, angiographic angiologist parameters in non-diabetic patients with critical chronic ischemia of lower limbs to a control group that will have been applied to a conventional treatment.

2. To analyze complications from regenerative therapy itself, from the route of administration and / or study procedures.


Recruitment information / eligibility

Status Completed
Enrollment 38
Est. completion date June 2015
Est. primary completion date June 2015
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 89 Years
Eligibility Inclusion Criteria:

- Patients of both sexes aged = 18 and = 89 years.

- Non-diabetic.

- Infrapopliteal atherosclerotic vascular disease with severe to severe claudication or Rutherford-Becker grade I-3, II, III, in at least one lower limb. The chronic critical ischemia of the lower limb is defined as persistent / recurring pain requiring analgesia and / or non-healing ulcers present> 4 weeks, with no evidence of improvement with conventional therapies and / or walking test (stress test) between 1-6 minutes two exercise tests separated by at least 2 weeks and / or ankle-brachial index at rest <0.8.

- Inability to endovascular or surgical revascularization as recommended by the TransAtlantic Inter-Society Consensus (TASC).

- Failure of the revascularization surgical performed at least 30 days before, either persistently or entry in critical ischemia phase.

- Life expectancy> 2 years.

- Not expected major amputation in the limb to treat in the next 6 months after inclusion.

- Normal laboratory parameters, defined by:

1. Leukocytes = 3000

2. Neutrophils = 1500

3. Platelets = 100,000

4. Aspartate aminotransferase AST) / Alanine aminotransferase (ALT) = 2.5 standard range institution.

5. Creatinine = 2.5 mg / dl

- Patients should give their written informed consent to participate in the study.

- Women of childbearing potential must have negative results on a pregnancy test following standard procedures for each hospital performed at the time of inclusion in the study and agree to use a medically approved method of contraception through the duration of the study.

Exclusion Criteria:

- History of malignancy or hematologic disease (myeloproliferative disease, myelodysplastic syndrome or leukemia)

- Patients with uncontrolled hypertension (defined as blood pressure> 180/110 on more than one occasion).

- Severe heart failure (New York Heart Association IV).

- Patients with malignant ventricular arrhythmias or unstable angina.

- Diagnosis of deep vein thrombosis in the previous 3 months.

- Active infection or gangrene wet day infusion of mononuclear bone marrow cells.

- Corporal mass index (BMI)> 40 kg/m2.

- Patients with a diagnosis of alcoholism at the time of inclusion.

- Proliferative retinopathy.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Other:
Intraarterial Infusion of Autologous Bone Marrow Mononuclear Cells
Autologous bone marrow-derived mononuclear cells will be infused by an intraarterial catheter into de ischemic limb. The number of infused cells will be 1x108, 5x108 and 1x109 low, intermediate and high dose in the arms respectively.

Locations

Country Name City State
Spain University Hospital Puerta del Mar Cádiz
Spain University Hospital Reina Sofía Cordoba
Spain University Hospital Virgen de las Nieves Granada
Spain University Hopistal Carlos Haya Málaga
Spain University Hospital Nuestra Señora de Valme Sevilla

Sponsors (2)

Lead Sponsor Collaborator
Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud Iniciativa Andaluza en Terapias Avanzadas

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Adverse events 6 months Yes
Secondary Ankle-brachial index 1 month, 3 months, 6 months No
Secondary Transcutaneous oxygen pressure (TcO2) 1 month, 3 months, 6 months No
Secondary Greater ulcer size Ulcer diameter will be recorded 1 month, 3 months, 6 months No
Secondary Degree of Rutherford-Becker 1 month, 3 months, 6 months No
Secondary Perimeter calf muscle 1 month, 3 months, 6 months No
Secondary Presence of faster opacity in infrapopliteal vessels at 6 months compared with the basal situation of the patient. 1 month, 3 month, 6 month No
See also
  Status Clinical Trial Phase
Terminated NCT02287974 - Clinical Trial I/II Opened, Randomized and Controlled for the Study of the Use of Stem Cells Therapy in Insulinized Diabetic Patients Type 2 With Critical Ischemia in Lower Limbs (CLI): Study of the Needs of Insulin Phase 1/Phase 2
Active, not recruiting NCT03006770 - Efficacy, Tolerability and Safety of Intramuscular Injections of PLX PAD for the Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization Phase 3
Completed NCT00987363 - Intraarterial Infusion of Autologous Bone Marrow in Diabetic Patients With Chronic Ischemia of Lower Limbs (CLI) no Revascularization Phase 1/Phase 2
Not yet recruiting NCT02538978 - Critical Limb Ischemia Rapid Delivery by SurgWerks-CLI Kit and VXP System Phase 3
Active, not recruiting NCT05208905 - LIFE-BTK PK Sub-study N/A
Recruiting NCT04849325 - IBS Titan vs. PTA in Patients With Infrapopliteal Arterial Stenosis or Occlusive Disease N/A
Completed NCT01257776 - Human Adipose Derived Mesenchymal Stem Cells for Critical Limb Ischemia (CLI) in Diabetic Patients Phase 1/Phase 2
Active, not recruiting NCT04227899 - LIFE-BTK Randomized Controlled Trial N/A
Terminated NCT03111238 - The Efficacy and Safety of REX-001 to Treat Ischemic Rest Pain in Subjects With CLI Rutherford Category 4 and DM Phase 3
Terminated NCT03174522 - The Efficacy and Safety of REX-001 to Treat Ischemic Ulcers in Subjects With CLI Rutherford Category 5 and DM Phase 3
Completed NCT01386216 - Safety Study of Bone Marrow Cell Concentrate Prepared Using the Magellan System to Treat Critical Limb Ischemia (CLI) Phase 1
Available NCT03886506 - Expanded Access Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization
Available NCT03746899 - Expanded Access for Treatment Use of PLX-PAD in Critical Limb Ischemia (CLI)